REMARKS ON PHYSICAL AND PSYCHOLOGICAL CHANGES IN PATIENTS WITH THYROID CANCER AFTER I-131 THERAPY

Nguyen Thi Anh1, Bui Minh Thu1, Doan Thi Ben1, Tran Dieu Thuy1, Phan Thi Thu Hue1, Dinh Tran Phuong1
1 Bach Mai Hospital

Main Article Content

Abstract

Objective: To assess physical and psychological changes in patients with thyroid cancer after I-131 therapy and to identify associated factors.


Methods: A cross-sectional descriptive study was conducted at Bach Mai Hospital from July 1 to November 30, 2025, among 140 patients with thyroid cancer who had undergone I-131 treatment, using convenience sampling. Data were collected using a general information questionnaire and the THYCA-QoL scale and analyzed with SPSS version 20.0.


Results: The mean overall physical-psychological change score was 41.0 ± 12.1 points (scale 0-100), ranging from 24 to 74 points. The most common symptoms were muscle and/or joint pain (35.7%), sudden fatigue (30.7%), palpitations (23.6%), anxiety (23.5%), hoarseness (22.9%), and leg cramps (22.9%). The overall score differed significantly by occupation (F = 3.78; p = 0.001) and educational level (F = 4.44; p < 0.05). Patients receiving high-dose I-131 had significantly higher change scores than those receiving low-dose treatment (43.51 ± 11.40 points vs. 37.35 ± 12.27 points; p = 0.003). Time since thyroidectomy showed a weak positive correlation with the overall score (r = 0.178; p = 0.04). No statistically significant associations were found between the overall score and sex, marital status, payment method, or comorbidities (p > 0.05).


Conclusion: Patients with thyroid cancer after I-131 therapy experience moderate levels of physical and psychological changes, with prominent musculoskeletal symptoms, fatigue, and anxiety. Long-term follow-up, symptom management, and psychological support are recommended, particularly for high-risk groups.

Article Details

References

[1] Perros P, Boelaert K et al. Guidelines for the management of thyroid cancer. Clinical Endocrinology, 2014, 81 (1): 1-122.
[2] Chow T.L. Quality of life after surgical treatment for thyroid cancer. JAMA Otolaryngol Head Neck Surg, 2019, 145 (9): 873. doi:10.1001/jamaoto.2019.175.
[3] McIntyre C, Jacques T et al. Quality of life in differentiated thyroid cancer. International Journal of Surgery, 2018, 50: 133-136. doi: 10.1016/j.ijsu.2017.12.014.
[4] Đậu Thị Hồng Nhung, Hồ Thị Kim Thanh. Chất lượng cuộc sống của bệnh nhân ung thư biểu mô tuyến giáp thể nhú và thế nang sau phẫu thuật cắt tuyến giáp. Tạp chí Nghiên cứu Y học, 2022, 151 (3): 63-72. doi: 10.52852/tcncyh.v151i3.604.
[5] Phạm Anh Tuấn, Từ Thị Hương Giang, Bùi Thị Kiều Oanh. Chất lượng cuộc sống của người bệnh ung thư tuyến giáp đã điều trị I-131 tại Bệnh viện Ung bướu Hà Nội. Tạp chí Y học Cộng đồng, 2025, 66 (CĐ20): 245-250. doi: 10.52163/yhc.v66iCD20.3623.
[6] Chan W.L, Choi H.C.W et al. Health-related quality of life in Asian differentiated thyroid cancer survivors. Cancer Control, 2021, 28, 10732748211029726. doi: 10.1177/10732748211029726.
[7] Maki Y, Horiuchi K, Okamoto T. Fatigue and quality of life among thyroid cancer survivors without persistent or recurrent disease. Endocrine Connections, 2022, 11 (2): e210506. doi: 10.1530/EC-21-0506.